SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
American Journal of Hospice and Palliative Medicine®
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Smith, H.
Right arrow Articles by Fishman, S. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Smith, H.
Right arrow Articles by Fishman, S. M.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Radiopharmaceuticals for palliation of painful osseous metastases

Howard Smith, MD

Division of Pain Management, Department of Anesthesiology, Albany Medical College, Albany, New York

Annu Navani, MD

Division of Pain Management, Department of Anesthesia, Stanford University School of Medicine, Stanford, California

Scott M. Fishman, MD

Division of Pain Medicine, Department of Anesthesiology and Pain Medicine, University of California, Davis, Sacramento, California

Bone metastases represent the most common etiology of pain for patients with advanced cancer. In the United States, the most common treatment for pain caused by bone metastases in late-stage cancer cases is external beam radiotherapy in conjunction with opioids. An alternative or adjuvant to external radiotherapy is intravenous radiopharmaceutical treatment. This review explores the pros and cons of different radiopharmaceutical options, their advantages over traditional external beam radiotherapy, and the conditions for optimal efficacy.

Key Words: cancer pain treatment • bisphosphonates • osseous metastases • radiopharmaceuticals • strontium-89 chloride 89Sr • hypercalcemia • phosphurous-32 • 32P • orthophosphate • rhenium-186 hydroxyethlidene • 186Re-HEDP • samarium-153 lexidronam • 153Sm-EDTMP • 117mSn-DTPA

American Journal of Hospice and Palliative Medicine®, Vol. 21, No. 4, 303-313 (2004)
DOI: 10.1177/104990910402100415
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?




Advertisement